Xenon Pharmaceuticals Inc... (XENE)
NASDAQ: XENE
· Real-Time Price · USD
37.81
-0.42 (-1.10%)
At close: Aug 18, 2025, 3:01 PM
Xenon Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -65.05M | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M | -48.46M | -47.46M | -41.73M | -37.4M | -37.15M | -31.16M | -19.67M | -25.56M | -15.45M | -22.11M | -15.76M |
Depreciation & Amortization | 659K | 633K | 669K | 659K | 599K | 851K | 1.73M | 602K | 354K | 515K | 358K | 375K | 376K | 270K | 209K | 231K | 196K |
Stock-Based Compensation | 12.17M | 13.6M | 13M | 14.72M | 9.4M | 9.18M | 8.74M | 8.45M | 5.99M | 5.81M | 5.74M | 5.21M | 3.61M | 2.71M | 2.64M | 2.7M | 1.97M |
Other Working Capital | n/a | 2.28M | -2.54M | 936K | -673K | -4.79M | -3.45M | 6.85M | 368K | -8.52M | -2.41M | 711K | -6.07M | -2.2M | -2.23M | 3.26M | -533K |
Other Non-Cash Items | n/a | 3.59M | -6.42M | 9.27M | 15.58M | 1.82M | -791K | -1.48M | -1.88M | -2.73M | 3.26M | 7.61M | 3.22M | 523K | 420K | 233K | -130K |
Deferred Income Tax | -1.21M | -8.43M | -322K | -333K | 403K | -196.97K | -156K | -224K | 288K | 5K | -203K | -104K | 258K | 346K | -267K | -30K | 9K |
Change in Working Capital | n/a | n/a | 4.72M | 936K | -5.65M | -598.89K | -3.3M | 6.89M | 2.56M | 1.07M | -2.4M | 6.89M | -6.23M | 1.01M | -2.57M | 5.89M | -6.98M |
Operating Cash Flow | -61.65M | -54.38M | -51.15M | -32.68M | -43.18M | -33.69M | -42.23M | -33.22M | -34.41M | -32.73M | -30.4M | -16.87M | -18.43M | -20.71M | -15.01M | -13.08M | -20.71M |
Capital Expenditures | -43K | -783K | -590K | -1.51M | -188K | -3.88K | -1.2M | -2.13M | -2.21M | -1.75M | -386K | -544K | -212K | -514K | -223K | -909K | -404K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 236.38M | -49.23M | -30.04M | -157.11M | -258.03M | 233.71M | n/a | -20.28M | -144.75M | n/a | n/a | -45.95M |
Purchase of Investments | -131.24M | -57.33M | -164.09M | -124.98M | -176.85M | -367.65M | -146.76M | -162.27M | -108.28M | -114.74M | -294.75M | -72.68M | -68.96M | -257.19M | -10M | -21.62M | -100.66M |
Sales Maturities Of Investments | n/a | 153.46M | 166.66M | 237.21M | 130.83M | 128.47M | 196M | 192.31M | 157.11M | 102.16M | 61.04M | 74.54M | 20.28M | 42.27M | 25.8M | 30.73M | 45.95M |
Other Investing Acitivies | 165.79M | -53.7K | 12.04K | n/a | 130.83M | -236.38M | 49.23M | 30.04M | 157.11M | 258.03M | -233.71M | 1.86M | 20.28M | 144.75M | 15.8M | 9.1M | 45.95M |
Investing Cash Flow | 34.51M | 98.5M | 1.98M | 110.72M | -46.2M | -239.18M | 48.03M | 27.9M | 46.62M | -14.34M | -234.1M | 1.32M | -48.89M | -215.43M | 15.57M | 8.19M | -55.1M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 1.15M | 47K | n/a | n/a | n/a | 35K | n/a | n/a | n/a | 6K | 699K | n/a | n/a | 15K | 28K | 111K | 106K |
Financial Cash Flow | 1.15M | 12.13M | n/a | n/a | n/a | 320.69M | 29.51M | n/a | n/a | 6K | 699K | 269.89M | 7.88M | 323.95M | 4.76M | 111K | 118.72M |
Net Cash Flow | -26.05M | 55.09M | -49.11M | 77.84M | -89.75M | 49.07M | 35.02M | -4.96M | 12.27M | -46.25M | -266.5M | 253.45M | -59.15M | 87.88M | 4.88M | -5.05M | 42.98M |
Free Cash Flow | -61.7M | -55.17M | -51.74M | -34.19M | -43.37M | -33.69M | -43.43M | -35.35M | -36.62M | -34.48M | -30.79M | -17.41M | -18.64M | -21.22M | -15.23M | -13.99M | -21.11M |